Get the Stockscreener App
1.61
2.42%
-0.04
After Hours:
1.63
0.02
+1.24%
Accelerate Diagnostics Inc stock is traded at $1.61, with a volume of 44,568.
It is down -2.42% in the last 24 hours and down -14.36% over the past month.
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
See More
Previous Close:
$1.65
Open:
$1.58
24h Volume:
44,568
Relative Volume:
0.72
Market Cap:
$40.57M
Revenue:
$12.00M
Net Income/Loss:
$-63.23M
P/E Ratio:
-0.2046
EPS:
-7.87
Net Cash Flow:
$-43.02M
1W Performance:
-5.29%
1M Performance:
-14.36%
6M Performance:
+16.67%
1Y Performance:
-64.85%
1-Day Range:
$1.58
$1.68
1-Week Range:
$1.58
$1.78
52-Week Range:
$0.73
$5.23
Accelerate Diagnostics Inc Stock (AXDX) Company Profile
Name
Accelerate Diagnostics Inc
Sector
Industry
Phone
303-863-8088
Address
3950 S. COUNTRY CLUB ROAD #470, TUCSON, AZ
Compare AXDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXDX
Accelerate Diagnostics Inc
|
1.61 | 40.57M | 12.00M | -63.23M | -43.02M | -7.87 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Accelerate Diagnostics Inc Stock (AXDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-22 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-08-20 | Initiated | BTIG Research | Neutral |
| Aug-07-20 | Upgrade | Craig Hallum | Hold → Buy |
| Sep-27-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-18 | Initiated | Craig Hallum | Hold |
| Dec-13-17 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-12-17 | Resumed | BTIG Research | Buy |
| Mar-24-16 | Initiated | JP Morgan | Overweight |
| Dec-16-15 | Initiated | Piper Jaffray | Overweight |
View All
Accelerate Diagnostics Inc Stock (AXDX) Latest News
Accelerate Diagnostics (NASDAQ:AXDX) Raised to “Hold” at StockNews.com - Defense World
Glox Therapeutics awarded grant to accelerate development of precision antibiotics - European Pharmaceutical Manufacturer
Microbial Identification Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031 - WhaTech
William Blair Has Bearish Estimate for AXDX FY2024 Earnings - Defense World
Armistice Capital, LLC's Strategic Acquisition in Accelerate Dia - GuruFocus.com
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2024 Earnings Call Transcript - Insider Monkey
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates - MSN
Accelerate Diagnostics: Q3 Earnings Snapshot - Houston Chronicle
Accelerate Diagnostics Reports Key Advances Amid Financial Challenges - TipRanks
Accelerate Diagnostics Reports Third Quarter 2024 Financial Results - StockTitan
Antimicrobial Susceptibility Testing Market is Expected to Soar in the Upcoming Years - openPR
Accelerate Diagnostics (NASDAQ:AXDX) Earns Sell Rating from Analysts at StockNews.com - Defense World
BeeKeeperAI, Topcon Healthcare Collaborating on Optical Diagnostics - MPO-mag
BNGOBionano Genomics, Inc. Latest Stock News & Market Updates - StockTitan
Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies - PR Newswire
StockNews.com Begins Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
AXDXAccelerate Diagnostics, Inc. Latest Stock News & Market Updates - StockTitan
Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results - Kilgore News Herald
Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Comparing Accelerate Diagnostics (NASDAQ:AXDX) & Advanced BioMedical Technologies (OTCMKTS:ABMT) - Defense World
Global study shows cefiderocol’s success in treating resistant infections - European Pharmaceutical Manufacturer
Antimicrobial Resistance Diagnostics Market to Witness an Outstanding Growth by 2032 - openPR
Antibiotic Sensitivity Testing Market Growth and Industry Overview - News in Assen
Accelerate Diagnostics (NASDAQ:AXDX) Research Coverage Started at StockNews.com - Defense World
Optical Imaging Market Size to Reach USD 5.61 Billion by 2033 | Straits Research - GlobeNewswire
Cytovale Completes $100 Million Series D Funding to Accelerate Commercial Expansion of its Rapid Sepsis Solution - PR Newswire
Saudi Arabia Diagnostic Imaging Market Will Accelerate Rapidly - openPR
Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System - Yahoo Finance
FDA approves Accelerate Arc system to identify microbial infections - Medical Device Network
FDA clears new system for rapid sepsis identification By Investing.com - Investing.com Australia
FDA clears new system for rapid sepsis identification - Investing.com
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System - StockTitan
Mindpeak secures $15.3M in series A funding to accelerate growth in AI-based digital pathology - Business Wire
Short Interest in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Drops By 12.6% - Defense World
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Stake Reduced by Armistice Capital LLC - Defense World
StockNews.com Initiates Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
Italy Antimicrobial Resistance Diagnostics Market Size & Outlook, 2030 - Grand View Research
North America Antimicrobial Resistance Diagnostics Market Size & Outlook, 2030 - Grand View Research
PersonalAIze and Cube Forge Groundbreaking Partnership to - GlobeNewswire
PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics - Yahoo Finance
Accelerate Diagnostics (NASDAQ:AXDX) Stock Crosses Above 200 Day Moving Average of $1.21 - Defense World
Veterinary Antimicrobial Susceptibility Testing Market: In-depth Analysis Of Market Trends, Technological A... - WhaTech
Blood Screening Market Advancements Highlighted by Size, Share, Growth Analysis, Business Insights And Fore... - WhaTech
Europe Point Of Care TB And Drug-resistant TB Testing Market | Report, 2030 - Grand View Research
North America Antibiotic Sensitivity Testing Market By Application - Third Eye News
RenovaroCube to Present Cutting-Edge Cancer Diagnostics - GlobeNewswire
Agilent Unveils Biopharma CDx Services Lab to Accelerate Precision Medicine - Business Wire
Chlamydia Infection Diagnostics And Therapeutics Global Market 2024Latest Trends, Technological Advancem... - WhaTech
Blood Culture Tests Market 2024: Pioneering Innovations in Diagnostic Healthcare As Discussed In New Market... - WhaTech Technology and Markets News
New Release of Ibex Medical Analytics AI-powered Platform to Accelerate Advancements in Cancer Diagnostics - Business Wire
Accelerate Diagnostics Inc Stock (AXDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):